{"id":"W4399881578","doi":"10.1016/j.cllc.2024.06.007","title":"MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC","year":2024,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"AstraZeneca","keywords":"Durvalumab; Medicine; Chemoimmunotherapy; Chemoradiotherapy; Chemotherapy; Oncology; Neoadjuvant therapy; Gemcitabine; Internal medicine; Stage (stratigraphy); Surgery; Cancer; Immunotherapy; Breast cancer; Nivolumab; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003830228,0.0004250933,0.001094162,0.0001882512,0.0002392697,0.000426398,0.0005256189,0.0003686037,0.003084523],"category_scores_gemma":[0.0003693971,0.0001648368,0.0005944746,0.0001611907,0.0003070962,0.0005546707,0.0004132962,0.000865611,0.0004615346],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006274742,"about_ca_system_score_gemma":0.000783544,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004720881,"about_ca_topic_score_gemma":0.003079632,"domain_scores_codex":[0.9998837,0.0000214793,0.00001395471,0.00002898311,0.00001138698,0.0000404255],"domain_scores_gemma":[0.9998697,0.00001997821,0.00001765453,0.0000135634,0.000003507197,0.00007566314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.267206,0.01007981,0.04656095,0.001968915,0.001413846,0.002925936,0.0003210811,0.00613403,0.05173987,0.002944344,0.01516335,0.5935419],"study_design_scores_gemma":[0.164347,0.3362699,0.3359883,0.001186227,0.002557406,0.01471307,0.0006275603,0.01630325,0.04119723,0.005640838,0.08090568,0.0002634759],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857422,0.005284576,0.0006371823,0.0008014129,0.0004575341,0.0003031777,0.0004591514,0.00007880756,0.006235877],"genre_scores_gemma":[0.9945205,0.001429745,0.001051614,0.0004445465,0.0001437074,0.0001965003,0.000827114,0.00001358926,0.001372606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003084523,"threshold_uncertainty_score":0.0103187,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04781090545811995,"score_gpt":0.4172892982631643,"score_spread":0.3694783928050444,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}